Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs

Oncogene

Volumn 21, Issue 41, 2002, Pages 6249-6254

  Blagosklonny, Mikhail V ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Checkpoints; G2 arrest; Mitosis; p53; Paclitaxel

Indexed keywords

7 HYDROXYSTAUROSPORINE; DOXORUBICIN; PACLITAXEL; PROTEIN BCL 2; PROTEIN P53; RAF PROTEIN; RETINOBLASTOMA PROTEIN;

ARTICLE; CELL CYCLE G2 PHASE; CELL DEATH; CELL KILLING; CONTROLLED STUDY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; MICROTUBULE; MITOSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL DEATH; G2 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HL-60 CELLS; HUMANS; JURKAT CELLS; MICROTUBULES; NEOPLASMS; PACLITAXEL;

EID: 0037068773     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1205793     Document Type: Article

References (26)

1. An WG, Hwang SG, Trepel JB and Blagosklonny MV. (2000). Leukemia, 14, 1276-1283.
2. Blagosklonny MV. (1999). Leukemia, 13, 2031-2035.
3. Blagosklonny MV. (2001). Leukemia, 15, 869-874.
4. Blagosklonny MV, Dixon SC, Robey R and Figg WD. (2001). Int. J. Oncol., 19, 257-262.
5. Blagosklonny MV and Pardee AB. (2001). Cancer Res., 61, 4301-4305.
6. Blagosklonny MV, Robey R, Bates S and Fojo T. (2000). J. Clin. Invest., 105, 533-539.
7. Blagosklonny MV, Robey R, Sheikh MS and Fojo T. (2002). Cancer Biol. Ther., 1, 113-117.
8. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B. (1998). Science, 282, 1497-1501.
9. Busby EC, Leistritz DF, Abraham RT, Karnitz LM and Sarkaria JN. (2000). Cancer Res., 60, 2108-2112.
10. Chan TA, Hwang PM, Hermeking H, Kinzler KW and Vogelstein B. (2000). Genes Dev., 14, 1584-1588.
11. Chang BD, Xuan Y, Broude EV, Zhu H, Schott B, Fang J and Roninson IB. (1999). Oncogene, 18, 4808-4818.
12. Giannakakou P, Robey R, Fojo T and Blagosklonny MV. (2001). Oncogene, 20, 3806-3813.
13. Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM and Piwnica-Worms H. (2000). J. Biol. Chem., 275, 5600-5605.
14. Hu B, Zhou XY, Wang X, Zeng ZC, Iliakis G and Wang Y. (2001). J. Biol. Chem., 276, 17693-17698.
15. Jordan MA and Wilson L. (1998). Curr. Opin. Cell Biol., 10, 123-130.
16. Kastan MB, Canman CE and Leonard CJ. (1995). Cancer Metastasis Rev., 14, 3-15.
17. Lau CC and Pardee AB. (1982). Proc. Natl. Acad. Sci. USA, 79, 2942-2946.
18. Li W, Fan J, Banerjee D and Bertino JR. (1999). Mol. Pharmacol., 55, 1988-1993.
19. Passalaris TM, Benanti JA, Gewin L, Kiyono T and Galloway DA. (1999). Mol. Cell. Biol., 19, 5872-5881.
20. Rowinsky EK and Donehower RC. (1995). N. Engl. J. Med., 332, 1004-1014.
21. Sherr CJ. (2002). Cell Cycle, 1, 36-38.
22. Smith APL, Gimenez-Abian JF and Clarke DJ. (2002). Cell Cycle, 1, 16-33.
23. Torres K and Horwitz SB. (1998). Cancer Res., 58, 3620-3626.
24. Vogelstein B, Lane D and Levine A. (2000). Nature, 408, 307-310.
25. Waldman T, Lengauer C, Kinzler KW and Vogelstein B. (1996). Nature, 381, 643-644.
26. Yu L, Orlandi L, Wang P, Orr MS, Senderowicz AM, Sausville EA, Silvestrini R, Watanabe N, Piwnica-Worms H and O'Connor PM. (1998). J. Biol. Chem., 273, 33455-33464.